furmonertinib 240 mg oral, daily + furmonertinib 160 mg oral, daily + platinum-based chemotherapy
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-Small Cell Lung Cancer
Conditions
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Trial Timeline
Jun 1, 2023 → Feb 15, 2028
NCT ID
NCT05607550About furmonertinib 240 mg oral, daily + furmonertinib 160 mg oral, daily + platinum-based chemotherapy
furmonertinib 240 mg oral, daily + furmonertinib 160 mg oral, daily + platinum-based chemotherapy is a phase 3 stage product being developed by ArriVent Biopharma for Metastatic Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05607550. Target conditions include Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05607550 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Non-Small Cell Lung Cancer